Propionic acid and neurofilament light chain in multiple sclerosis

2026/07/01 by Sofia Sandgren, David Leppert, Jens Kühle · 1 voice
Biochemistry, Genetics and Molecular Biology · Medicine · #Amyotrophic Lateral Sclerosis Research #Multiple Sclerosis Research Studies #Skin and Cellular Biology Research

paper · doi:10.1093/brain/awag192

openalex publication_date 2026/07/01 · openalex created_date 2026/07/06 · openalex updated_date 2026/07/07

Abstract

This scientific commentary refers to ‘Propionic acid in multiple sclerosis: a phase 2b, double blind, randomized placebo-controlled trial’, by Moser et al. (https://doi.org/10.1093/brain/awag099).

Citations

• Short-chain fatty acids: linking diet, the microbiome and immunity
• Propionic acid in multiple sclerosis: a phase 2b, double-blind, randomized placebo-controlled trial

Discussions

• Propionic acid and neurofilament light chain in multiple sclerosis #NeuroDegeneration 🧪🧠 http://doi.org/10.1093/brain/awag192 [bsky, 0 points, 0 comments]

Related

• Propionic acid in multiple sclerosis: a phase 2b, double-blind, randomized placebo-controlled trial
• Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis
• Amyotrophic lateral sclerosis as a network disease: from metabolic decline to network failure
• High-efficacy therapy and progression independent of relapse and MRI activity in multiple sclerosis
• MYELIN-ASSOCIATED RADIATION EMISSION IN MULTIPLE SCLEROSIS: Radioactivity, Chemiluminescence, or Quantum Mechanical Photon Entanglement?